1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. YARROW BIOSCIENCE INC.
Yarrow Bioscience Inc.
XNAS: YARW
19.71-0.16(-0.81%)
162.2K
XNAS Volume

XNAS 09 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Yarrow Bioscience Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Yarrow Bioscience Inc share price target, revenues, EPS, net income and more

Yarrow Bioscience Inc quarterly results: revenue, profit, and P&L – 13 quarter history

  • POSITIVE

    Quarterly Revenue Yarrow Bioscience Inc Jun-2026 Quarterly Revenue is $0 Million which is growth of 40.6% YoY.

  • POSITIVE

    Quarterly Net Profit Yarrow Bioscience Inc Jun-2026 Quarterly Net Profit is $-3 Million which is growth of 47.7% YoY.

Yarrow Bioscience Inc., Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
0.10.20.10.20.10.10.20.10.10.10.1
Cost Of Rev.
-------------
Gross Profit
-------------
⌄
3.22.9187.69.412.913.210.67.56.96.410.5
Operating Profit
-3.1-2.9-1-7.8-7.5-9.2-12.8-13.1-10.4-7.4-6.8-6.2-10.3
-0.1-----------
Profit Before Tax
-2.9-2.7-71-7.4-5.8-8.6-12-12.2-9.4-6.2-6.2-6.1-10
Tax
⌄
-3-2.8-71-7.3-5.8-8.6-12-12.2-9.4-6.3-6.2-6.6-10.1
Diluted NI Avail to Com Stockholders Ann.
-3-2.8-71-7.3-5.8-8.6-12-12.2-9.4-6.3-6.2-6.6-10.1
Basic EPS
-1.1-1-25.3-8.5-2.1-10-14-14.5-11-7.5-22-100.5-154.5
Diluted EPS After ExtraOrdinary
-1-1-0.4-8.5-2.1-10-14-14.5-11-7.5-21.8-92.5-154
Number Of Shares End
2.82.82.80.92.80.90.90.90.90.90.30.10.1
Net Income Continuing Discontinued Operations
-3-2.8-71-7.3-5.8-8.6-12-12.2-9.4-6.3-6.2-6.6-10.1
Normalized Income
-2.3-2.4-1-7.4-5.8-8.6-12-12.2-9.4-6.2-6.2-6.1-10
Interest Income
-0.1-----------
Interest
-------------
Net Interest Income
-0.1-----------
EBIT
-2.9-2.9-71-7.8-5.8-9.2-12.8-13.1-10.4-7.4-6.8-6.2-10.3
EBITDA
-2.9-2.9-71-7.8-7.5-9.2-12.8-13.1-10.4-7.4-6.8-6.2-10.3
Reconciled Cost Of Rev.
-------------
Reconciled Depr.
-00000----
Profit From Continuing Operations
-3.9-2.8-71-7.3-5.8-8.6-12-12.2-9.4-6.3-6.2-6.6-10.1
Normalized EBITDA
-3.1-2.969-7.8-7.5-9.2-12.8-13.1-10.4-7.4-6.8-6.2-10.3
*All financials are in USD Million and price data in USD

Yarrow Bioscience Inc competitor comparison and performance snapshot within industry

Yarrow Bioscience Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

  • POSITIVE

    Annual Revenue Yarrow Bioscience Inc Dec-2025 Annual Revenue is $1 Million which is growth of 13.8% YoY.

  • POSITIVE

    Annual Net Profit Yarrow Bioscience Inc Dec-2025 Annual Net Profit is $-26 Million which is growth of 33.5% YoY.

Yarrow Bioscience Inc., Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
6.3%
-50.9%
 0.60.50.40.514.82110.64.60.7
Cost Of Rev. Ann.
-
-
 ----3.41.4-----
Gross Profit Ann.
-
-
 ----11.419.6-----
Operating Exp. Ann.
-4.5%
-25.6%
1530.344.129.734.879.4133.176.265.234.2154.6
Operating Profit Ann.
-
-
-14.8-29.8-43.6-29.3-34.3-68-113.5-76.2-54.5-29.6-14.3-4.6
-
-
 ----5.6-4.42.53.10.50.3
Other Exp. Ann.
95.7%
-
 33.81.40.4-0.1-138-----
PBT Ann.
-
-
-84.1-26.7-39.8-27.9-33.9-73.8-255.8-73.7-51.4-29.1-14.1-4.6
Tax Ann.
-
-
00-0.5-0.3-----
⌄
-
-
-84-26.5-39.8-28.5-23.2-73.3-255.6-73.7-51.5-29.1-14.1-4.6
Diluted NI Avail to Com Stockholders Ann.
-
-
-84-26.5-39.8-28.5-23.2-73.3-255.6-73.7-51.5-29.1-14.1-4.6
EPS Ann.
-
-
 -31-46.5-139-364-1,278-7,092-11,124-8,532-5,083.2-4,968-1,437.8
Diluted EPS Ann.
-
-
 -31-46.5-139-364-1,278-7,092-11,124-8,532-5,083.2-4,968-1,437.8
Number Of Shares End
203.7%
94.7%
 2.80.90.30.10.10.1000-
Total Exp. Ann.
-4.5%
-25.8%
 30.344.129.734.882.8134.576.265.234.2154.6
Net Income Continuing Discontinued Operations Ann.
-
-
-84-26.5-39.8-28.5-23.2-73.3-255.6-73.7-51.5-29.1-14.1-4.6
Normalized Income Ann.
-
-
-13.2-26.7-39.8-27.9-34-73.3-116.6-73.7-51.5-29.1-14.1-4.6
Interest Income Ann.
-
-
 -----------
Interest Ann.
-
-
 ---5.64.4-----
EBITDA Ann.
-
-
-84.5-29.7-43.6-29.3-33.9-68.1-251.1-75.5-54.5-29.6-14.3-4.6
Reconciled Cost Of Rev. Ann.
-
-
 ----3.41.4-----
Reconciled Depr. Ann.
-
-
 00.10.10.30.700-
Profit From Continuing Operations Ann.
-
-
-84.9-26.5-39.8-28.5-23.2-73.3-255.6-73.7-51.4-29.1-14.1-4.6
Normalized EBITDA Ann.
-
-
55.3-29.7-43.6-29.3-33.9-68.1-112-75.5-54.5-29.6-14.3-4.6
*All financials are in USD Million and price data in USD
Total Rev. Ann.
1Y CHG
20%
2Y CAGR
22.5%
3Y CAGR
6.3%
5Y CAGR
-50.9%
7Y CAGR
-33.7%
Total Revenue Annual growth is higher than historical averages.
Operating Exp. Ann.
1Y CHG
-31.3%
2Y CAGR
1%
3Y CAGR
-4.5%
5Y CAGR
-25.6%
7Y CAGR
-10.4%
10Y CAGR
20.7%
Operating Expenses Annual Cr is falling faster than historical averages.

Yarrow Bioscience Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

  • NEGATIVE

    Total Shareholders Fund Yarrow Bioscience Inc Dec-2025 Total Shareholders Fund is $-71 Million which is growth of -236.3% YoY.

  • POSITIVE

    Total Assets Yarrow Bioscience Inc Dec-2025 Total Assets is $100 Million which is growth of 50.1% YoY.

Yarrow Bioscience Inc., Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
35%
1.4%
100.466.997.740.867.193.779.2139.966.942.143.9
⌄
95.4%
4.9%
71.614.899.618.456.310.79.6123.971.559.8
⌄
-
-
-7152.188.731.248.637.568.5130.4-57-29.4-16
Total Capitalization Ann.
-2.5%
-16.4%
28.952.188.731.248.670.768.5130.4-57-29.4-16
Tangible Assets Ann.
-2.5%
-5.1%
28.952.188.731.248.637.568.5130.4-57-29.4-16
Working Capital Ann.
-0.5%
-15.4%
28.549.688.428.944.865.867.71305627.643.1
Invested Capital Ann.
-
-
-7152.188.731.248.670.768.5130.4-57-29.4-16
Tangible Book Value Ann.
-
-
-7152.188.731.248.637.568.5130.4-57-29.4-16
Borrowings Ann.
-37%
-32.2%
0.10.20.434.80.7----
Net Debt Ann.
-
-
-----------
Share Issued Ann.
203.7%
94.7%
2.80.30.30.10.10.100000
Number Of Shares End
203.7%
94.7%
2.80.90.30.10.10.1000-
*All financials are in USD Million and price data in USD
Total Assets Ann.
1Y CHG
50.1%
2Y CAGR
1.4%
3Y CAGR
35%
5Y CAGR
1.4%
7Y CAGR
-4.6%
10Y CAGR
8.6%
Total Assets Annual growth is higher than historical averages.
Total Current Liabilities Ann.
1Y CHG
383.8%
2Y CAGR
209%
3Y CAGR
97.5%
5Y CAGR
27.2%
7Y CAGR
33.4%
10Y CAGR
56.7%
Total Current Liabilities Annual Cr growth is higher than historical averages.

Yarrow Bioscience Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

  • NEGATIVE

    Book Value Per Share Yarrow Bioscience Inc Book Value Per Share is $42 which is growth of -80.1% YoY.

  • NEUTRAL

    ROE Yarrow Bioscience Inc ROE is 0% which is growth of 0% YoY.

Yarrow Bioscience Inc., Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
RoA Ann. %
-
-
--48.40%-41.10%-43.06%-91.21%-295.61%-67.28%-49.75%-53.39%-32.74%-10.50%
ROE Ann. %
-
-
--56.57%-47.44%-58.14%-170.28%-482.20%-74.12%-140.29%---
ROIC %
-
-
--20.8-12.3-27.9-21.2-28.2-27.4-12.7---
OPM Ann. %
-
-
-5,219.12%-8,709.98%-6,900.47%-7,189.73%-461.08%-540.54%--512.55%-645.85%-2,126.41%-
Inventory Turnover Ratio Ann.
-
-
----0.50.2-----
Asset Turnover Ann. %
-
-
-0000.20.2-0.10.10-
Working Capital Turnover Ann.
-
-
0000.30.30.10.10
Quick Ratio Ann.
-
-
-4.212.43.92.73.57.214.37.77.956.9
Current Ratio Ann.
-
-
-4.412.74.13.44.17.414.68.28.157
Interest Coverage Ratio Ann.
-
-
-----12.2-57.3-----
LT Debt To Equity Ann.
-
-
----0.9-----
*All financials are in USD Million and price data in USD

Yarrow Bioscience Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

  • POSITIVE

    Cash From Operating Activity Yarrow Bioscience Inc Dec-2025 Cash From Operating Activity is $-33 Million which is growth of 2.5% YoY.

  • POSITIVE

    Net Cash Flow Yarrow Bioscience Inc Dec-2025 Net Cash Flow is $4 Million which is growth of 138.2% YoY.

Yarrow Bioscience Inc., Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
-
-
-33.1-34-25.3-29.2-56.4-137.1-65.1-52.7-28.3-2.3-4.2
33.6%
-15.9%
37.423.4-57.415.7189.141.4-33.9-15.1-37.5-
-
-
-0.1-0.182.41.739.861.85125.949.5-47.7
Cash Plus Cash Eqv. End Of Year Ann.
-8.2%
-16.3%
2419.930.73142.958.430.849.510.2443.8
Net Increase In Cash Plus Cash Eqv.s Ann.
-
-21.6%
4.1-10.8-0.3-11.9-15.613.8-18.739.36.2-39.843.5
Cash Plus Cash Eqv. Begin Of Year Ann.
-22.6%
-14.9%
19.930.73142.958.444.649.510.2443.80.3
Income Tax Paid Supplemental Data Ann.
-
-
-----------
Interest Paid Supplemental Data Ann.
-
-
---2.43.9-----
Capex Ann.
-
-
--0.1----0.1-0-0.1-0-0-
Issuance Of Capital Stock Ann.
-
-
-82.81.77661.64.5125.450.3-47.6
Issuance Of Debt Ann.
-
-
----------
Repayment Of Debt Ann.
-
-
----36.4------
Repurchase Of Capital Stock Ann.
-
-
--0.4--------
Free Cash Flow Ann.
-
-
-33.1-34.1-25.3-29.2-56.4-137.2-65.1-52.9-28.3-2.3-4.2
*All financials are in USD Million and price data in USD
Cash from Investing Act. Ann.
1Y CHG
59.8%
3Y CAGR
33.6%
5Y CAGR
-15.9%
Cash from Investing Activity Annual growth is stable compared to historical averages.